Paper42983151PubMed
H3K18 lactylation promotes osteosarcoma cell proliferation and migration through transcriptional activation of m6A reader YTHDF2.
Peng M and 6 others. In Vitro Cell Dev Biol Anim, 2026.
Cite this record
ConductScience Library. H3K18 lactylation promotes osteosarcoma cell proliferation and migration through transcriptional activation of m6A reader YTHDF2. Papers, record 42983151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42983151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- H3K18 lactylation promotes osteosarcoma cell proliferation and migration through transcriptional activation of m6A reader YTHDF2.
- Journal
- In Vitro Cell Dev Biol Anim
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-04
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33734139 | Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. | Chin Med J (Engl) | 2021 | https://conductscience.org/library/papers/33734139 | PubMed |
| 2 | 36614339 | Correction: Chen et al. The Chemerin/CMKLR1 Axis Is Involved in the Recruitment of Microglia to Aβ Deposition through p38 MAPK Pathway. Int. J. Mol. Sci. 2022, 23, 9041. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36614339 | PubMed |
| 3 | 38033505 | Long non-coding RNA PRR7-AS1 promotes osteosarcoma progression via binding RNF2 to transcriptionally suppress MTUS1. | Front Oncol | 2023 | https://conductscience.org/library/papers/38033505 | PubMed |
| 4 | 32829036 | Clinical efficiency of epigenetic drugs therapy in bone malignancies. | Bone | 2021 | https://conductscience.org/library/papers/32829036 | PubMed |
| 5 | 34216543 | Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. | Mol Cell | 2021 | https://conductscience.org/library/papers/34216543 | PubMed |
| 6 | 36856188 | Lactylation: novel epigenetic regulatory and therapeutic opportunities. | Am J Physiol Endocrinol Metab | 2023 | https://conductscience.org/library/papers/36856188 | PubMed |
| 7 | 41940424 | Ginkgolide A Suppresses Osteosarcoma Proliferation and Activates the Apoptotic Pathway by Targeting the KAT2A-H3K18la Lactylation Axis. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/41940424 | PubMed |
| 8 | 34131316 | Advancing therapy for osteosarcoma. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/34131316 | PubMed |
| 9 | 17320500 | Epigenetics: a landscape takes shape. | Cell | 2007 | https://conductscience.org/library/papers/17320500 | PubMed |
| 10 | 35732125 | Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. | Cell Rep | 2022 | https://conductscience.org/library/papers/35732125 | PubMed |
| 11 | 40683951 | MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma. | Cell Death Differ | 2025 | https://conductscience.org/library/papers/40683951 | PubMed |
| 12 | 42245633 | Lactylation-driven metabolic reprogramming promotes osteosarcoma malignancy via HDGF-mediated proliferation and immune modulation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42245633 | PubMed |
| 13 | 39662272 | m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis. | Int Immunopharmacol | 2025 | https://conductscience.org/library/papers/39662272 | PubMed |
| 14 | 38512058 | Dux activates metabolism-lactylation-MET network during early iPSC reprogramming with Brg1 as the histone lactylation reader. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38512058 | PubMed |
| 15 | 34150616 | Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer. | Front Oncol | 2021 | https://conductscience.org/library/papers/34150616 | PubMed |
| 16 | 40868849 | Epigenetic Modifications in Osteosarcoma: Mechanisms and Therapeutic Strategies. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40868849 | PubMed |
| 17 | 33121495 | YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. | Mol Cancer | 2020 | https://conductscience.org/library/papers/33121495 | PubMed |
| 18 | 37615625 | Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. | Autophagy | 2024 | https://conductscience.org/library/papers/37615625 | PubMed |
| 19 | 35765275 | KLF5-induced miR-487a augments the progression of osteosarcoma cells by targeting NKX3-1 in vitro. | Oncol Lett | 2022 | https://conductscience.org/library/papers/35765275 | PubMed |
| 20 | 36621008 | Lactate, histone lactylation and cancer hallmarks. | Expert Rev Mol Med | 2023 | https://conductscience.org/library/papers/36621008 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42983151
GET https://conductscience.org/api/papers/v1/42983151/references?page=2